Expedition Therapeutics is a biotechnology company developing novel therapies for serious inflammatory and respiratory diseases. The company's lead program, EXPD-101, is a next-generation once-daily DPP1 inhibitor with first-in-class potential in COPD and first/best-in-class potential across a broad spectrum of other neutrophil-driven diseases. Expedition combines deep translational expertise, clinical development experience, and a platform for in-licensing global innovation.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
10/09/25	$165,000,000	Series A	Adage Capital Management Balyasny Asset Management BVF Partners Dawn Biopharma Forbion Capital Partners Logos Capital Novo Holdings Sanofi Ventures Sofinnova Investments Venrock Healthcare Partners	undisclosed
08/09/26	$115,000,000	Series B	Adage Capital Management Balyasny Asset Management BVF Partners Dawn Biopharma Forbion Capital Partners General Atlantic Logos Capital Novo Holdings RA Capital Sanofi Ventures Sofinnova Investments Venrock Healthcare Partners Vivo Capital	undisclosed
08/10/26	$115,000,000	Series B	Adage Capital Management Balyasny Asset Management BVF Partners Dawn Biopharma Forbion Capital Partners General Atlantic Logos Capital Novo Holdings RA Capital Management Sanofi Ventures Sofinnova Investments Venrock Healthcare Partners Vivo Capital	undisclosed